Abstract

Carbonic anhydrase inhibitors form an accepted form of treatment in the glaucomas. They have been accepted in the treatment of chronic simple glaucoma even on a long-term basis. A number of such agents which are now on the market have been tested as hypotensive agents. Becker (1954) introduced acetazolamide (Diamox) as the first hypotensive agent; Leopold (1958) described the action of dichlorphenamide; Langham (1958) discussed the effect of methazolamide (Neptazane) on the intraocular pressure. Posner (1958) and Drance (1959) discussed the action of ethoxzolamide (Cardrase) on the intraocular pressure in man. In spite of the availability of carbonic anhydrase inhibitors, the search continues for powerful carbonic anhydrase inhibitors which would require less frequent administration and produce less in the way of side-effects in patients. It is still true that side-effects and intolerance constitute the main reason for cessation of therapy with these agents. The present study was under-taken to evaluate

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call